CD80 Antibody, anti-human, REAfinity™
Synonyms: B7, B7-1, BB1
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
38 Citations16 Images
Clone:
REA661 | 2D10
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD80 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
PE-Vio 670
Vio Bright B515
Vio Bright R720
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-117-719, 130-117-831
Description:
Immature human monocyte-derived dendritic cells were stained with CD80 antibodies or with the corresponding REA Control (S) antibodies (left peak). CD209+ cells were pre-gated for the analysis. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application image
Extended validation for CD80 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA661
2D10
high
QA18A16
high
W17149D
high
L307.4
partial

Cells were incubated with an excess of purified unconjugated CD80 (REA661) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CD80 knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD80-PE (REA661, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD80 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD80-PE, clone (REA661). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD80. Immature MoDc cells were stained with CD80 antibodies and with a suitable counterstaining. As a control, CD80 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD80 (REA661). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD80 Antibody, anti-human, REAfinity™
Overview

Clone REA661 recognizes the human CD80 antigen, also known as B7-1. CD80 is a 262 amino acid long 60 kDa molecule and a member of the immunoglobulin superfamily. Together with CD86 (B7-2) it belongs to the B7 family of costimulatory molecules. CD80 is expressed on activated B cells, dendritic cells, and monocytes/ macrophages. The interaction of CD80 with its ligands CD28 and CD152 (CTLA-4) plays a critical role in induction and regulation of immune responses. Binding of CD80 to CD28, which is constitutively expressed on T cells, provides a costimulatory signal and induces T cell proliferation and cytokine production. In contrast, binding to CTLA-4 strongly inhibits proliferation and IL-2 secretion by T cells.

Additional information: Clone REA661 displays negligible binding to Fc receptors.

Alternative names

B7, B7-1, BB1

Detailed product information

Technical specifications

Clone
REA661
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, non-human primate
Cross-reactivity
rhesus monkey (Macaca mulatta)
Antigen
CD80
Molecular mass of antigen [kDa]
29
Distribution of antigen
T cells, B cells, dendritic cells, Langerhans cells, macrophages, monocytes
Entrez Gene ID
RRID
AB_2921855, AB_2928568, AB_2659257, AB_2802016, AB_2802032, AB_2928567, AB_2751414, AB_2659256, AB_2921838, AB_2751432

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD80 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support